MabCure Inc
MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, In… Read more
MabCure Inc (MBCI) - Total Liabilities
Latest total liabilities as of December 2011: $935.15K USD
Based on the latest financial reports, MabCure Inc (MBCI) has total liabilities worth $935.15K USD as of December 2011.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
MabCure Inc - Total Liabilities Trend (2007–2011)
This chart illustrates how MabCure Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
MabCure Inc Competitors by Total Liabilities
The table below lists competitors of MabCure Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Patient Portal Technologies Inc
PINK:PPRG
|
USA | $5.65 Million |
|
Velocity Energy Inc
PINK:VCYE
|
USA | $14.11 Million |
|
Urologix Inc
PINK:ULGX
|
USA | $13.09 Million |
|
Interplay Entertainment Corp
PINK:IPLY
|
USA | $3.42 Million |
|
Pacific Conquest Holdings Inc
PINK:PCHK
|
USA | $31.66K |
|
Andatee China Marine Fuel Services
PINK:AMCF
|
USA | $197.56 Million |
|
CTPartners Executive Search Inc
PINK:CTPR
|
USA | $58.18 Million |
|
Next.e.GO N.V. Ordinary Shares
NASDAQ:EGOX
|
USA | $190.03 Million |
Liability Composition Analysis (2007–2011)
This chart breaks down MabCure Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MabCure Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MabCure Inc (2007–2011)
The table below shows the annual total liabilities of MabCure Inc from 2007 to 2011.
| Year | Total Liabilities | Change |
|---|---|---|
| 2011-12-31 | $935.15K | +93.81% |
| 2010-12-31 | $482.51K | -42.08% |
| 2009-12-31 | $833.04K | +190.79% |
| 2008-12-31 | $286.48K | +481.50% |
| 2007-12-31 | $49.27K | -- |